EP3383914A4 - Anticorps anti-ox40 et leurs procédés d'utilisation - Google Patents

Anticorps anti-ox40 et leurs procédés d'utilisation Download PDF

Info

Publication number
EP3383914A4
EP3383914A4 EP16871651.2A EP16871651A EP3383914A4 EP 3383914 A4 EP3383914 A4 EP 3383914A4 EP 16871651 A EP16871651 A EP 16871651A EP 3383914 A4 EP3383914 A4 EP 3383914A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16871651.2A
Other languages
German (de)
English (en)
Other versions
EP3383914A1 (fr
Inventor
Nicholas S. Wilson
Jeremy D. WAIGHT
Ekaterina V. Breous-Nystrom
Gerd Ritter
David SCHAER
Daniel HIRSCHHORN-CYMERMAN
Taha MERGHOUB
Volker Seibert
Marc VAN DIJK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Memorial Sloan Kettering Cancer Center
Agenus Inc
Original Assignee
Ludwig Institute for Cancer Research Ltd
Memorial Sloan Kettering Cancer Center
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Memorial Sloan Kettering Cancer Center, Agenus Inc filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP3383914A1 publication Critical patent/EP3383914A1/fr
Publication of EP3383914A4 publication Critical patent/EP3383914A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP16871651.2A 2015-12-02 2016-12-02 Anticorps anti-ox40 et leurs procédés d'utilisation Withdrawn EP3383914A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262371P 2015-12-02 2015-12-02
PCT/US2016/064794 WO2017096281A1 (fr) 2015-12-02 2016-12-02 Anticorps anti-ox40 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3383914A1 EP3383914A1 (fr) 2018-10-10
EP3383914A4 true EP3383914A4 (fr) 2019-10-30

Family

ID=58797926

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16871651.2A Withdrawn EP3383914A4 (fr) 2015-12-02 2016-12-02 Anticorps anti-ox40 et leurs procédés d'utilisation

Country Status (3)

Country Link
EP (1) EP3383914A4 (fr)
MA (1) MA43389A (fr)
WO (1) WO2017096281A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
WO2018089628A1 (fr) 2016-11-09 2018-05-17 Agenus Inc. Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
KR20210157471A (ko) 2016-12-15 2021-12-28 애브비 바이오테라퓨틱스 인크. 항-ox40 항체 및 이의 용도
EP3704159A1 (fr) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Anticorps agonistes immunostimulateurs destinés à être utilisés dans le traitement du cancer
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
JP2021519298A (ja) 2018-03-27 2021-08-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 紫外線シグナルを使用した力価のリアルタイムモニタリング
WO2019214624A1 (fr) * 2018-05-11 2019-11-14 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps entièrement humains dirigés contre ox40, procédé de préparation correspondant, et utilisation associée
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
WO2020014583A1 (fr) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Combinaison d'agoniste d'ox-40, d'inhibiteur de la voie pd-1 et d'inhibiteur ctla-4 destinée à être utilisée dans un procédé de traitement d'un cancer ou d'une tumeur solide
SG11202103568PA (en) * 2018-10-23 2021-05-28 Magenta Therapeutics Inc Fc silenced antibody drug conjugates (adcs) and uses thereof
WO2020142626A1 (fr) * 2019-01-04 2020-07-09 Gigagen, Inc. Protéines de liaison anti-ox40 et méthodes d'utilisation de celles-ci
WO2020172658A1 (fr) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Procédés d'isolement d'une protéine
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
JP2022532930A (ja) 2019-05-23 2022-07-20 ブリストル－マイヤーズ スクイブ カンパニー 細胞培養培地をモニターする方法
EP3976832A1 (fr) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o)
WO2020243570A1 (fr) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Signature de localisation cellulaire et polythérapie
WO2020243563A1 (fr) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Signatures géniques multi-tumorales destinées à être adaptées à une thérapie immuno-oncologique
CA3142513A1 (fr) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Proteines de fusion flt3l-fc et procedes d'utilisation
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
EP4045083B1 (fr) 2019-10-18 2024-01-10 Forty Seven, Inc. Polythérapies pour le traitement de syndromes myélodysplasiques et de la leucémie myéloïde aiguë
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
WO2021113765A1 (fr) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Méganucléases modifiées optimisées ayant une spécificité pour une séquence de reconnaissance dans un génome du virus de l'hépatite b
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
US12110294B2 (en) 2020-05-01 2024-10-08 Gilead Sciences, Inc. CD73 compounds
EP4153181A1 (fr) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Compositions pharmaceutiques contenant du bictégravir
PE20230779A1 (es) 2020-08-07 2023-05-09 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
CN114106173A (zh) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
JP2023538955A (ja) 2020-08-31 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在シグネチャーおよび免疫療法
KR20230080460A (ko) 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 단백질을 농축시키는 방법
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230107288A (ko) 2020-11-11 2023-07-14 길리애드 사이언시즈, 인코포레이티드 gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
WO2022146948A1 (fr) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Administration sous-cutanée d'anticorps pd1/pd-l1
WO2022146947A1 (fr) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
KR20230127306A (ko) 2020-12-31 2023-08-31 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK)세포 관여자
WO2022212876A1 (fr) 2021-04-02 2022-10-06 The Regents Of The University Of California Anticorps dirigés contre un cdcp1 clivé et leurs utilisations
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
WO2023076983A1 (fr) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Dérivés de pyridine-3(2h)-one
MX2024005066A (es) 2021-10-29 2024-05-24 Gilead Sciences Inc Compuestos de cd73.
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
EP4440702A1 (fr) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Composés thérapeutiques contre l'infection par le virus du vih
WO2023102523A1 (fr) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Composés thérapeutiques pour l'infection par le virus du vih
WO2023107956A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et 5t4
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023122581A2 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023173011A1 (fr) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Expression transitoire de protéines thérapeutiques
IL315083A (en) 2022-03-17 2024-10-01 Gilead Sciences Inc The IKAROS family of zinc fingers degrades and uses them
WO2023178329A1 (fr) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Procédés d'isolement de polypeptides
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023235847A1 (fr) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
WO2024006982A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (fr) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci
WO2024044477A1 (fr) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Régime de dosage et de planification pour anticorps largement neutralisants
WO2024054992A1 (fr) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Procédés de séparation d'agent chélateur
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024076915A1 (fr) 2022-10-04 2024-04-11 Gilead Sciences, Inc. Analogues de 4'-thionucléosides et leur utilisation pharmaceutique
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024196952A1 (fr) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Évaluation de sous-type de tumeur pour une thérapie anticancéreuse

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2009030237A2 (fr) * 2007-09-07 2009-03-12 Symphogen A/S Méthodes de production recombinante d'anticorps anti-rsv
EP2356270B1 (fr) * 2008-11-07 2016-08-24 Fabrus Llc Bibliothèques combinatoires d'anticorps et leurs utilisations
PT2560993T (pt) * 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
ES2630328T3 (es) * 2010-08-23 2017-08-21 Board Of Regents, The University Of Texas System Anticuerpos anti-OX40 y procedimientos de uso de los mismos
CN106102774A (zh) * 2013-12-17 2016-11-09 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAHRUKH HUSENI ET AL: "Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. Suppl 3, 6 November 2014 (2014-11-06), pages P253, XP021202522, ISSN: 2051-1426, DOI: 10.1186/2051-1426-2-S3-P253 *

Also Published As

Publication number Publication date
EP3383914A1 (fr) 2018-10-10
WO2017096281A1 (fr) 2017-06-08
MA43389A (fr) 2021-05-12

Similar Documents

Publication Publication Date Title
IL282962A (en) Anti-PD-1 antibodies and methods of using them
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
HK1250513A1 (zh) 抗ox40抗體及其使用方法
HK1249445A1 (zh) 抗分揀蛋白抗體和其使用方法
HK1252698A1 (zh) 抗siglec-9抗體及其使用方法
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
HK1252696A1 (zh) 抗siglec-7抗體及其使用方法
EP3230319B8 (fr) Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
ZA201606630B (en) Anti-ox40 antibodies and methods of use
EP3177322A4 (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
HK1259251A1 (zh) 人源化抗c1s抗體及其使用方法
EP3116911B8 (fr) Anticorps anti-mcam et procédés d'utilisation associés
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EP3390442A4 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3134121A4 (fr) Nouveaux anticorps anti-rnf43 et méthodes d'utilisation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3189079A4 (fr) Nouveaux anticorps anti-mfi2 et méthodes d'utilisation
HK1256094A1 (zh) 抗-htra1抗體及其使用方法
EP3559042A4 (fr) Anticorps anti-lilrb3 et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BREOUS-NYSTROM, EKATERINA V.

Inventor name: SEIBERT, VOLKER

Inventor name: MERGHOUB, TAHA

Inventor name: WILSON, NICHOLAS S.

Inventor name: WAIGHT, JEREMY D.

Inventor name: VAN DIJK, MARC

Inventor name: SCHAER, DAVID

Inventor name: RITTER, GERD

Inventor name: HIRSCHHORN-CYMERMAN, DANIEL

A4 Supplementary search report drawn up and despatched

Effective date: 20191002

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20190926BHEP

Ipc: G01N 33/68 20060101ALI20190926BHEP

Ipc: A61K 39/395 20060101ALI20190926BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260993

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210409

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240305